116 related articles for article (PubMed ID: 31006597)
1. Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy.
Harries I; Biglino G; Baritussio A; De Garate E; Dastidar A; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2019 Oct; 292():248-252. PubMed ID: 31006597
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
Neilan TG; Coelho-Filho OR; Pena-Herrera D; Shah RV; Jerosch-Herold M; Francis SA; Moslehi J; Kwong RY
Am J Cardiol; 2012 Dec; 110(11):1679-86. PubMed ID: 22917553
[TBL] [Abstract][Full Text] [Related]
4. Long-term prognostic value of right ventricular dysfunction on cardiovascular magnetic resonance imaging in anthracycline-treated cancer survivors.
Chhikara S; Hooks M; Athwal PSS; Hughes A; Ismail MF; Joppa S; Velangi PS; Nijjar PS; Blaes AH; Shenoy C
Eur Heart J Cardiovasc Imaging; 2022 Aug; 23(9):1222-1230. PubMed ID: 34297807
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
[TBL] [Abstract][Full Text] [Related]
6. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
Neilan TG; Coelho-Filho OR; Shah RV; Feng JH; Pena-Herrera D; Mandry D; Pierre-Mongeon F; Heydari B; Francis SA; Moslehi J; Kwong RY; Jerosch-Herold M
Am J Cardiol; 2013 Mar; 111(5):717-22. PubMed ID: 23228924
[TBL] [Abstract][Full Text] [Related]
7. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
Muehlberg F; Funk S; Zange L; von Knobelsdorff-Brenkenhoff F; Blaszczyk E; Schulz A; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2018 Aug; 5(4):620-629. PubMed ID: 29673122
[TBL] [Abstract][Full Text] [Related]
8. Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study.
Harries I; Biglino G; Ford K; Nelson M; Rego G; Srivastava P; Williams M; Berlot B; De Garate E; Baritussio A; Liang K; Baquedano M; Chavda N; Lawton C; Shearn A; Otton S; Lowry L; Nightingale AK; Carlos Plana J; Marks D; Emmanueli C; Bucciarelli-Ducci C
Int J Cardiol Heart Vasc; 2022 Dec; 43():101134. PubMed ID: 36389268
[TBL] [Abstract][Full Text] [Related]
9. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
[TBL] [Abstract][Full Text] [Related]
10. Correlation between right ventricular T
Jellis CL; Yingchoncharoen T; Gai N; Kusunose K; Popović ZB; Flamm S; Kwon D
Int J Cardiovasc Imaging; 2018 Jan; 34(1):55-65. PubMed ID: 28357724
[TBL] [Abstract][Full Text] [Related]
11. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J
Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422
[TBL] [Abstract][Full Text] [Related]
12. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.
Toro-Salazar OH; Gillan E; O'Loughlin MT; Burke GS; Ferranti J; Stainsby J; Liang B; Mazur W; Raman SV; Hor KN
Circ Cardiovasc Imaging; 2013 Nov; 6(6):873-80. PubMed ID: 24097420
[TBL] [Abstract][Full Text] [Related]
13. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping.
Haslbauer JD; Lindner S; Valbuena-Lopez S; Zainal H; Zhou H; D'Angelo T; Pathan F; Arendt CA; Bug G; Serve H; Vogl TJ; Zeiher AM; Carr-White G; Nagel E; Puntmann VO
Int J Cardiol; 2019 Jan; 275():179-186. PubMed ID: 30360992
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.
Segura AM; Radovancevic R; Demirozu ZT; Frazier OH; Buja LM
Tex Heart Inst J; 2015 Apr; 42(2):124-30. PubMed ID: 25873821
[TBL] [Abstract][Full Text] [Related]
16. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer.
Ylänen K; Poutanen T; Savikurki-Heikkilä P; Rinta-Kiikka I; Eerola A; Vettenranta K
J Am Coll Cardiol; 2013 Apr; 61(14):1539-47. PubMed ID: 23500246
[TBL] [Abstract][Full Text] [Related]
17. Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy.
Schelbert EB; Elkayam U; Cooper LT; Givertz MM; Alexis JD; Briller J; Felker GM; Chaparro S; Kealey A; Pisarcik J; Fett JD; McNamara DM;
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28373243
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
[TBL] [Abstract][Full Text] [Related]
19.
Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
[TBL] [Abstract][Full Text] [Related]
20. Fat deposition in dilated cardiomyopathy assessed by CMR.
Lu M; Zhao S; Jiang S; Yin G; Wang C; Zhang Y; Liu Q; Cheng H; Ma N; Zhao T; Chen X; Huang J; Zou Y; Song L; He Z; An J; Renate J; Xue H; Shah S
JACC Cardiovasc Imaging; 2013 Aug; 6(8):889-98. PubMed ID: 23850250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
